Skip to main content

Choices across treatment lines: Maximising patient outcomes in advanced or metastatic NSCLC

ELCC 2017 – Industry satellite symposium

Chaired by Luis Paz-Ares with Egbert Smit and Benjamin Besse​​​​​​​

Held on Saturday 6th May 2017, Palexpo, Geneva, Switzerland

This symposium provides practical advice for clinicians treating NSCLC in an increasingly intricate therapeutic landscape. The expert Faculty guides the audience through case studies covering the harder-to-treat squamous NSCLC patient and the increasingly complex problem of what is the best approach for adenocarcinoma patients who rapidly progress.

Scientific summary

© Springer Healthcare IME

Learning objectives

Following attendance at this symposium delegates should be able to:

  • Explain the remaining high unmet therapeutic needs for patients with advanced squamous NSCLC in comparison to those with adenocarcinoma.
  • Describe the optimal treatment path for advanced non-squamous NSCLC patients who rapidly progress during first-line therapy, and highlight the benefits of various therapeutic approaches to maximise individual patient outcomes.
  • Debate the latest research which could further improve outcomes for patients with NSCLC.

Faculty bios

Educational grant

This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.

Produced by Springer Healthcare IME.

Contact Us

Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK